Treats hypertension. ANDA 79245, held by Aurobindo Pharma. Fosinopril Sodium; Hydrochlorothiazide.
As of Nov 21, 2026, ANDA 79245 (Fosinopril Sodium and Hydrochlorothiazide), held by Aurobindo Pharma, was first approved by FDA on Jul 9, 2009, with 2 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Fosinopril sodium and hydrochlorothiazide tablets are indicated for the treatment of hypertension. These fixed dose combinations are not indicated for initial therapy. (See DOSAGE AND ADMINISTRATION. ) In using fosinopril sodium and hydrochlorothiazide, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that fosinopril does not have a similar risk (see WARNINGS: Neutropenia/Agranulocytosis ).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 9, 2009 | Original application | Approved | None posted |
| Fosinopril Sodium and Hydrochlorothiazide10MG;12.5MG · tablet;oral | Fosinopril Sodium; Hydrochlorothiazide | Rx |
| Fosinopril Sodium and Hydrochlorothiazide20MG;12.5MG · tablet;oral | Fosinopril Sodium; Hydrochlorothiazide | Rx |
| Aug 20, 2020 | Supplement 12Labeling · Standard review | Approved | None posted |
| Jan 3, 2014 | Supplement 5Labeling · Standard review | Approved | None posted |
| Jul 9, 2009 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters